Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf124 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Hirofumi Miyake und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Tenri Hospital, Nara, Japan. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Cyclophosphamide, Rituximab, Immunosuppressive Agents. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objectives
To compare the efficacy and safety of rituximab (RTX) to those of intravenous cyclophosphamide (IVCY) as remission induction therapy in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and severe renal impairment.
Methods
Using the REVEAL cohort, this retrospective multicentre study enrolled 96 newly diagnosed patients with AAV and an estimated glomerular filtration rate of < 30 ml/min/1.73 m2. The patients were divided into RTX and IVCY groups. Matching weights were used to adjust for baseline characteristics. The primary outcome was a 2-year composite of all-cause mortality or end-stage kidney disease (ESKD). Secondary outcomes included all-cause mortality, ESKD, relapse, and hospitalisation-requiring infections. Outcomes were assessed using multivariable Cox proportional hazards models.
Results
In the weighted population, the hazard ratio for RTX versus IVCY was 0.73 (95% confidence interval: 0.31–1.72) for the primary composite outcome, with no significant intergroup difference. Similarly, intergroup differences in the hazard ratios for all-cause mortality, ESKD, relapses, and hospitalisation-requiring infections were not significant.
Conclusions
RTX and IVCY demonstrated comparable efficacy in preventing mortality and ESKD in this high-risk population. RTX is a viable option for patients with AAV and severe renal impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan.
- Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Rheumatology, Kobe City Medical Center General Hospital, Hyogo, Japan.
- Division of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital, Osaka, Japan.
- Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.
ORCID-Profile: Hirofumi Miyake, Takuya Kotani, Ryu Watanabe, Motomu Hashimoto, Hideki Oka, Shuji Sumitomo, Ryosuke Hiwa
Zitieren
APA
Miyake, H., Okazaki, A., Matsuda, S., Masuda, Y., Kotani, T., Hatta, M., Shiomi, M., Watanabe, R., Hashimoto, M., Oka, H., Sumitomo, S., Jo, K., Fujiki, Y., Yamamoto, W., Taniguchi, T., Shoji, M., Manabe, A., & Hiwa, R. (2025). Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf124
Vancouver
Miyake H, Okazaki A, Matsuda S, Masuda Y, Kotani T, Hatta M, et al. Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf124
BibTeX
@article{Miyake2025,
author = {Miyake, Hirofumi and Okazaki, Ayana and Matsuda, Shogo and Masuda, Yuichi and Kotani, Takuya and Hatta, Muneyuki and Shiomi, Mayu and Watanabe, Ryu and Hashimoto, Motomu and Oka, Hideki and Sumitomo, Shuji and Jo, Kaho and Fujiki, Yohei and Yamamoto, Wataru and Taniguchi, Tomoki and Shoji, Mikihito and Manabe, Atsushi and Hiwa, Ryosuke},
title = {Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf124}
}
EUVIMED